Description

1. Product Overview: Hepanib is a tablet formulation of Sorafenib Tosylate INN 200 mg, a targeted anticancer agent classified as a multikinase inhibitor used in the treatment of various advanced cancers.
2. Composition: Active Ingredient: Sorafenib Tosylate INN 200 mg | Dosage Form: Tablet
3. Pharmacological Class: Multikinase Inhibitor (Targeted Anticancer Therapy)
4. Mechanism of Action: Sorafenib inhibits multiple intracellular and cell surface kinases involved in tumor cell proliferation and angiogenesis, including RAF kinases, VEGFR, and PDGFR, leading to reduced tumor growth and blood supply.
5. Indications: Hepatocellular carcinoma (liver cancer) | Advanced renal cell carcinoma | Differentiated thyroid carcinoma
6. Dosage & Administration: As prescribed by oncologist | Oral use | Typically taken twice daily on an empty stomach | Swallow tablets whole
7. Clinical Benefits: Inhibits tumor growth and angiogenesis | Slows disease progression | Improves survival outcomes in advanced cancers
8. Contraindications: Hypersensitivity to Sorafenib or any component
9. Precautions: Monitor liver function and blood pressure | Risk of hand-foot skin reaction | Use under specialist supervision
10. Drug Interactions: May interact with CYP3A4 inducers/inhibitors and anticoagulants
11. Special Populations: Pregnancy contraindicated | Lactation not recommended | Pediatric safety not established | Use cautiously in hepatic impairment
12. Adverse Effects: Diarrhea | Fatigue | Hand-foot skin reaction | Hypertension | Rash
13. Storage Conditions: Store below 30°C | Protect from light and moisture | Keep out of reach of children
14. Packaging: Tablet in blister pack
15. Manufacturer: Everest Pharmaceutical Ltd.